Published February 27, 2026 | Version v1
Dataset Open

LITERATURE REVIEW: PARKINSON'S DISEASE

  • 1. Dean of the Faculty of Medicine, Alfraganus University, Ph.D. in Medical Sciences, Associate Professor

Description

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein aggregates known as Lewy bodies. Clinically, the disease presents with cardinal motor symptoms such as resting tremor, bradykinesia, and rigidity, while a wide range of non-motor manifestations—including cognitive impairment, autonomic dysfunction, sleep disturbances, and mood disorders—often precede motor onset. Modern therapeutic strategies are primarily symptomatic and aim to restore dopaminergic transmission through pharmacological treatments or deep brain stimulation. Despite significant advances, no current therapy effectively halts or reverses neurodegeneration. Ongoing research focuses on biomarkers, genetic mechanisms, immunotherapies targeting α-synuclein, and neuroprotective approaches to modify disease progression.

Files

2374-2377.pdf

Files (311.7 kB)

Name Size Download all
md5:9c87a483f0a16ca0c7c598d7f25a9201
311.7 kB Preview Download

Additional details

References

  • .Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284–2303.
  • 2.Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., ... & Lang, A. E. (2017). Parkinson disease. Nature Reviews Disease Primers, 3, 17013.
  • .Kalia, L. V., & Lang, A. E. (2015). Parkinson's disease. The Lancet, 386(9996), 896–912.
  • .Braak, H., Del Tredici, K., Rüb, U., de Vos, R. A., Jansen Steur, E. N., & Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197–211
  • .Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18, 435–450.